Brain and other central nervous system tumor statistics, 2021
2021/08/24 by Kimberly D. Miller, Quinn T. Ostrom, Carol Kruchko +10 · 32 citations
Medicine · #Glioma Diagnosis and Treatment #Brain Metastases and Treatment #Acute Lymphoblastic Leukemia research
paper · doi:10.3322/caac.21693
Abstract
Brain and other central nervous system (CNS) tumors are among the most fatal cancers and account for substantial morbidity and mortality in the United States. Population-based data from the Central Brain Tumor Registry of the United States (a combined data set of the National Program of Cancer Registries [NPCR] and Surveillance, Epidemiology, and End Results [SEER] registries), NPCR, National Vital Statistics System and SEER program were analyzed to assess the contemporary burden of malignant and nonmalignant brain and other CNS tumors (hereafter brain) by histology, anatomic site, age, sex, and race/ethnicity. Malignant brain tumor incidence rates declined by 0.8% annually from 2008 to 2017 for all ages combined but increased 0.5% to 0.7% per year among children and adolescents. Malignant brain tumor incidence is highest in males and non-Hispanic White individuals, whereas the rates for nonmalignant tumors are highest in females and non-Hispanic Black individuals. Five-year relative survival for all malignant brain tumors combined increased between 1975 to 1977 and 2009 to 2015 from 23% to 36%, with larger gains among younger age groups. Less improvement among older age groups largely reflects a higher burden of glioblastoma, for which there have been few major advances in prevention, early detection, and treatment the past 4 decades. Specifically, 5-year glioblastoma survival only increased from 4% to 7% during the same time period. In addition, important survival disparities by race/ethnicity remain for childhood tumors, with the largest Black-White disparities for diffuse astrocytomas (75% vs 86% for patients diagnosed during 2009-2015) and embryonal tumors (59% vs 67%). Increased resources for the collection and reporting of timely consistent data are critical for advancing research to elucidate the causes of sex, age, and racial/ethnic differences in brain tumor occurrence, especially for rarer subtypes and among understudied populations.
Citations
Cited by
- NeXtBrain: Combining local and global feature learning for brain tumor classification
- Charting the single-cell and spatial landscape of IDH-wild-type glioblastoma with GBmap
- Tumor microenvironment in glioblastoma: The central role of the hypoxic–necrotic core
- Leveraging the Mononuclear Phagocyte System for Advancing Glioma Theranostics: Current Insights and Future Directions
- Global cancer mortality among children, adolescents, and young adults from 77 countries, 1990–2021: a global time-series analysis and modelling study
- A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities
- A Novel Nomogram for Predicting Meningioma Grade Based on Radiomics Features and Clinical Characteristics
- Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics. [europepmc]
- Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy. [europepmc]
- Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment. [europepmc]
- Liquid Biopsy in Glioblastoma. [europepmc]
- Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. [europepmc]
- Tumor-derived exosomes deliver the tumor suppressor miR-3591-3p to induce M2 macrophage polarization and promote glioma progression. [europepmc]
- Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. [europepmc]
- Molecular Engines, Therapeutic Targets, and Challenges in Pediatric Brain Tumors: A Special Emphasis on Hydrogen Sulfide and RNA-Based Nano-Delivery. [europepmc]
- Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing. [europepmc]
- DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis. [europepmc]
- Signaling pathways in brain tumors and therapeutic interventions. [europepmc]
- Imaging of Lymphomas Involving the CNS: An Update-Review of the Full Spectrum of Disease with an Emphasis on the World Health Organization Classifications of CNS Tumors 2021 and Hematolymphoid Tumors 2022. [europepmc]
- Advanced MR Techniques for Preoperative Glioma Characterization: Part 1. [europepmc]
- Enzyme-Triggered Chemodynamic Therapy via a Peptide-H 2 S Donor Conjugate with Complexed Fe 2 . [europepmc]
- Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment. [europepmc]
- Glioblastoma heterogeneity at single cell resolution. [europepmc]
- Targeting IGF2BP3 in Cancer. [europepmc]
- Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019. [europepmc]
- Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. [europepmc]
- Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers. [europepmc]
- Artificial intelligence-based MRI radiomics and radiogenomics in glioma. [europepmc]
- Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives. [europepmc]
- Lipid-based nanoparticles as drug delivery carriers for cancer therapy. [europepmc]
- Immunotherapy for glioblastoma: current state, challenges, and future perspectives. [europepmc]
- Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. [europepmc]
Related